GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval GlobeNewswire Sep 23, 2024 5:30am
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update GlobeNewswire Sep 19, 2024 8:10pm
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis GlobeNewswire Jul 26, 2024 11:45am